Stephen Flach

发表

Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug‐Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open‐Label Studies in Healthy Subjects

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical pharmacology in drug development.

Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical and translational science.

Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical Drug Investigation.

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Omeprazole, a Proton Pump Inhibitor, in Healthy Subjects

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical pharmacology in drug development.

Omecamtiv mecarbil does not prolong QTc intervals at therapeutic concentrations

Cheng-Pang Hsu, B. Darpo, S. Dutta, 2021, British journal of clinical pharmacology.

Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Adult Subjects

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical Drug Investigation.

Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects

Cheng-Pang Hsu, S. Dutta, Hanze Zhang, 2021, Clinical pharmacology in drug development.

Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator

S. Dutta, Hanze Zhang, Edward Lee, 2021, Biopharmaceutics & drug disposition.

Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

B. Gufford, L. Galitz, Stephen Flach, 2021, Clinical pharmacology in drug development.

Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical Pharmacokinetics.

Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans

J. Chodakewitz, D. Dean, Sanjeev Kumar, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil

S. Dutta, Hanze Zhang, Edward Lee, 2021, Clinical pharmacology in drug development.

Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.

C. Caracta, E. G. Gil, Fanying Li, 2012, Biopharmaceutics & drug disposition.

Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects

W. Symonds, M. Berrey, Stephen Flach, 2012, Antimicrobial Agents and Chemotherapy.

Healthy volunteers in first‐in‐human oncology drug development for small molecules

N. Steeghs, L. Vidal, Lesley Reeve, 2021, British journal of clinical pharmacology.

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants

C. Caracta, Stephen Flach, J. Jansat, 2012, Journal of clinical pharmacology.